Illumina, Inc. (ILMN)

Market Cap	19.23B
Revenue (ttm)	4.50B
Net Income (ttm)	-1.16B
Shares Out	158.90M
EPS (ttm)	-7.34
PE Ratio	n/a
Forward PE	140.35
Dividend	n/a
Ex-Dividend Date	n/a

Volume	949,095
Open	121.97
Previous Close	122.87
Day's Range	116.91 - 122.04
52-Week Range	89.00 - 213.91
Beta	1.19
Analysts	Buy
Price Target	174.20 (+43.91%)
Earnings Date	May 2, 2024

About ILMN

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regio...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 28, 2000
• Employees: 13,360
• Stock Exchange: NASDAQ
• Ticker Symbol: ILMN

Financial Performance

In 2023, Illumina's revenue was $4.50 billion, a decrease of -1.75% compared to the previous year's $4.58 billion. Losses were -$1.16 billion, -73.64% less than in 2022.

Analyst Forecast

According to 18 analysts, the average rating for ILMN stock is "Buy." The 12-month stock price forecast is $174.2, which is an increase of 43.91% from the latest price.

Price Target

$174.2

(43.91% upside)

Analyst Consensus: Buy